Drug Approval | March 17, 2022
Lynparza reduced risk of death by 32% in the adjuvant treatment of patients with breast cancer
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
The facility will enable research initiatives in analytical chemistry, biopharmaceuticals, and life sciences
The USFDA has granted a qualified infectious disease product (QIDP) designation to WCK 6777, which signifies its ability to meet unmet medical needs and facilitates a faster approval process
The investment will accelerate the overall Sarclisa development program
OCE+ uses IQVIA’s industry-leading data and advanced analytics to deliver AI-driven recommendations directly into the daily workflows of life sciences commercial teams
Machine learning approach to systems biology combined with ligand discovery platform
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
MTBVAC is a global public-private project that will be a milestone in the field of vaccinology
Empowers the lab to do more in less time within the existing floor plan by integrating clinical chemistry and immunoassay testing onto a single platform
The centre will initially employ 170 engineers, bringing the total number of Boston Scientific’s R&D employees in India to more than 300
Subscribe To Our Newsletter & Stay Updated
